CHE

CHE

USD

Chemed Corp

$555.740+7.730 (1.411%)

Prix en Temps Réel

Healthcare
Medical Care Facilities
États-Unis

Graphique des Prix

Métriques Clés

Métriques de Marché
Fondamentaux de l'Entreprise
Statistiques de Trading

Métriques de Marché

Ouverture

$548.010

Haut

$559.950

Bas

$541.810

Volume

0.00M

Fondamentaux de l'Entreprise

Capitalisation Boursière

8.1B

Industrie

Medical Care Facilities

Pays

United States

Statistiques de Trading

Volume Moyen

0.12M

Bourse

NYQ

Devise

USD

Intervalle sur 52 Semaines

Bas $512.12Actuel $555.740Haut $623.61

Rapport d'Analyse IA

Dernière mise à jour: 19 avr. 2025
Généré par l'IASource des Données: Yahoo Finance, Bloomberg, SEC

[CHE: Chemed Corp] Stock Check-Up: Earnings Ahead, Price Wobbles - What's Next?

Stock Symbol: CHE Generate Date: 2025-04-19 08:04:13

Alright, let's take a look at Chemed Corp (CHE). For those not deep in finance-speak, this company is in healthcare, specifically hospice care, and also owns Roto-Rooter. So, a bit of a mix, but both are pretty steady businesses. Here's what the recent news and numbers are telling us, in plain English.

News Buzz: A Bit of Both

The news feed is giving us two main points. First, Chemed is going to announce their first quarter earnings on April 23rd, with a conference call the next day. This is pretty standard stuff for public companies. Basically, they'll tell us how they did financially for the first three months of the year. No real sentiment here, just a heads-up that news is coming.

Second, we've got an analyst at RBC Capital who's still positive on Chemed. They're saying "Outperform" (which is analyst-speak for "they think it'll do better than average") and even raised their price target to $667. That's a bump up from their previous target of $633. This is definitely a good sign – someone who studies these things for a living thinks the stock has room to grow. So, overall, the news is slightly positive, leaning on that analyst upgrade.

Price Check: Up and Down Lately

Now, let's peek at the stock price itself over the last month or so. Looking at the numbers, it's been a bit of a rollercoaster. Back in late January and February, the price was mostly drifting downwards, kind of in the $550 range. Then, around late February, things jumped up – pretty sharply, actually. It climbed into the high $500s and even touched the low $600s in March. But lately, in April, it's been pulling back again. The last price we see is around $581.

So, what does this price action tell us? It looks like there was a strong upward move, but it lost some steam recently. We're currently seeing a bit of a dip. Now, the AI prediction folks are saying they expect the price to nudge down a little bit today and the next couple of days – not a huge drop, but a slight downward trend.

Putting It Together: Wait and See, Maybe Watch for a Dip?

Okay, so we've got slightly positive analyst vibes, a stock price that's pulled back recently, and AI predictions of a small further dip. What's the takeaway?

Right now, it feels like a "hold" or "wait-and-see" situation. The upcoming earnings report is a big question mark. Good earnings could give the stock a boost, especially with that analyst already feeling positive. Bad earnings? Well, that could push it down further.

If you're thinking about buying Chemed, this recent dip might be setting up an interesting entry point. The recommendation data even flags around $580 as a potential entry area, noting it's close to a support level. And looking at the price history, that $580 area has seemed to act as support before. So, if the price drifts a bit lower, say towards $580 or even slightly below, it could be a spot to consider getting in, if you're bullish on the company long-term.

On the flip side, if you already own Chemed, you might be watching that $555 area as a potential stop-loss. If the price falls below that, it could signal more downside. For taking profits, the recommendation data suggests around $593, but given the recent price action, that might be a bit close. Perhaps look at higher levels if the stock rebounds after earnings, maybe closer to that analyst target of $667, but that's a longer-term view.

Key thing to remember: Earnings are coming up soon. That's the big event to watch. How the market reacts to those earnings will likely dictate the short-term direction of Chemed's stock price.

Company Context Quick Note: Chemed being in hospice care is worth keeping in mind. It's a sector that can be less sensitive to economic ups and downs compared to some others. And Roto-Rooter? People always need plumbing help, right? So, they've got a bit of stability built into their business mix.

Disclaimer: Just a friendly reminder, this is just my take on the data, like chatting with a friend about stocks. It's not financial advice. Do your own homework, maybe talk to a real financial advisor before making any moves with your money. Stocks can go up and down, and you could lose money. Be smart out there!

Actualités Connexes

BusinessWire

Chemed Reports First-Quarter 2025 Results

Chemed Corporation (Chemed) (NYSE:CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation's largest providers of end-of-life care, and Roto-Rooter, the nation's largest commercial and residential

Voir plus
Chemed Reports First-Quarter 2025 Results

Prédiction IABeta

Recommandation IA

Baissier

Mis à jour le: 28 avr. 2025, 10:08

BaissierNeutreHaussier

60.0% Confiance

Risque et Trading

Niveau de Risque3/5
Risque Moyen
Adapté Pour
Modéré
Guide de Trading

Point d'Entrée

$555.28

Prise de Bénéfices

$566.87

Stop Loss

$533.32

Facteurs Clés

Le PDI 8.6 est au-dessus du MDI 8.2 avec un ADX de 15.4, suggérant une tendance haussière
Le cours actuel est extrêmement proche du niveau de support ($556.69), suggérant une forte opportunité d'achat
Le volume de transactions est 7.4x la moyenne (2,018), indiquant une pression d'achat extrêmement forte
Le MACD 1.0239 est en dessous de la ligne de signal 1.3625, indiquant un croisement baissier

Restez Informé

Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.